10/584018
IAP20 Rec'd PCT/PTO 21 JUN 2006

CULLEN & CO.
— Patent & Trade Mark Attorneys —

11 May 2005

By facsimile

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20
SWITZERLAND

Dear Colleagues,

Re:	International Patent Application No. PCT/AU2004/001800
Title:	Glycosaminoglycan (GAG) Mimetics
Applicant:	Progen Industries Limited
Our Ref:	031392PC/KF

We refer to the International Search Report and Written Opinion.

On behalf of the applicant, we wish to file claim amendments under Article 19, specifically:

Claims 1 and 2 are amended;

Claims 3-14 are unchanged.

We **enclose** new pages 51-53 containing claims 1-14 with the above changes.

Yours sincerely,
CULLEN & CO.

KEN FINNEY
TB

Enc. New claims

Correspondence
GPO Box 1074
Brisbane QLD 4001
Australia

Offices
Brisbane
Gold Coast
Townsville

ABN 81 339 219 581

Brisbane Office
Level 26
239 George Street, Brisbane
QLD 4000 Australia

Telephone +61 7 3011 5555
Facsimile +61 7 3229 3384
+61 7 3229 6598
Email mail@cullens.com.au
Website www.cullens.com.au

HELMUT A. EICHBERGER ** BE (Elec) GradIEAust FIPTA
CLAUDE ANESE *†• BE (Hons) MEngSc DipLaw FIPTA
IAN de JONGE ** BSc (Hons) PhD DipLegS MRACI FIPTA
KENNETH G. FINNEY ** BSc (Hons) PhD GradDipIP FIPTA
MICHAEL L. ANGLISS ** BSc FIPTA
ELISA McCUTCHEON *†# LLB BSc FIPTA
GARY W. NOCK * BE (Chem) (Hons) FIPTA
GINT SILINS *# BSc (Hons) PhD FIPTA
DAVID MORGAN * BE (Elec & Comp) (Hons) MIP FIPTA
WENDY DEAR †■ MIL LLB (Hons) BCLL
REGAN GOURLEY ■ BCom LLB BEng (Chem) (Hons) Grad IEAust
LETITIA de LIMA ■ BA(Communications)(Hons) GradDip TMLaw Trade Mark Attorney
CLARISSA WYNNE BSc (Hons) PhD
IRENE ELLUL BJL AFAIM, Practice Manager

* Patent and Trade Mark Attorney - Australia and New Zealand † Legal Practitioner • Partner # Associate
■ Registered Trade Mark Attorney

BEST AVAILABLE COPY

10/584018
IAP20 Rec'd PCT/PTO 21 JUN 2006

CLAIMS

1. A compound of the formula



I

wherein:

each X is independently CH_2, C(O), N, O, S, S(O), $S(O)_2$, or is a bond; and

each of R_1 to R_5 is independently a bond or is selected from the group consisting of:

hydrogen;

halogen;

azide;

an R group defined as C1 to C8 alkyl or alkenyl, aryl or heteroaryl optionally further substituted by:

an alkoxy, aryl, heteroaryl or aryloxy group;

-COOH, $-S(O)_2OH$, phosphate, carboxylate or tetrazolyl;

$-S(O)_2OH$, -S(O)OH, -S(O)R, $S(O)_2R$, $-S(O)_2NH_2$, $-S(O)_2OR$,

-S(O)OR;

-C(O)R;

phosphate, carboxylate or tetrazolyl;

an unsubstituted or substituted heterocylic group, wherein the substitution is by:

an alkyl or aryl group, $-CH_2NHC(O)R$, $-CH_2N(C(O)R)_2$, $-CH_2OR$,

wherein R is as defined above;

connected to a different R_1 to R_5 to form a new cyclic group;

a substructure based upon a group of the following formula:



II

wherein:

Y is H, R or –C(O)R, wherein R is as defined above;

at least one, but not more than two of R_7 to R_{11} is independently a structure according to formula **I**; or

a structure comprising a second unit according to formula **II** linked via a "Y" group wherein each unit is independently substituted by R_7 to R_{10};

with the provisos that:

when R_1 is $-CH_3$, $-S(O)_2OH$ or -H at least one of R_2 to R_5 is not -H or $-S(O)_2OH$;

when a substructure of type **II** is not present and none of R_1-R_5 form an anhydro bridge, no more than two of R_1-R_5 are $-S(O)_2OH$ and the stereochemistry of **I** is not gluco or galacto;

2. A compound according to claim 1, wherein said compound is PG2024, PG2037, PG2173, PG2198, as hereinbefore described.

3. A compound according to claim 1, wherein said compound is any one of the compounds of Tables 1-4 of the description.

4. A pharmaceutical or veterinary composition for the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation, coagulation, thrombosis, and/or microbial infection, which composition comprises at least one compound according to claim 1 together with a pharmaceutically or veterinarially acceptable carrier or diluent for said at least one compound.

5. The composition according to claim 4 which further includes a pharmaceutically or veterinarially acceptable excipient, buffer, stabiliser, isotonicising agent, preservative or antioxidant.

6. The composition according to claim 4, wherein said compound is present therein as an ester, a free acid or base, a hydrate, or a prodrug.

7. Use of a compound according to claim 1 in the manufacture of a medicament for the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation, coagulation, thrombosis, and/or microbial infection.

8. The use according to claim 7, wherein said mammalian subject is a human subject.

9. A method for the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation, coagulation, thrombosis, and/or microbial infection, which method comprises administering to the subject an effective amount of at least one compound according to claim 1, or a composition comprising said at least one compound.

10. The method according to claim 9 wherein said mammalian subject is a human subject.

11. The method according to claim 9, wherein said disorder resulting from angiogenesis is a proliferative retinopathy or angiogenesis resulting from the growth of a solid tumour.

12. The method according to claim 9, wherein said disorder resulting from inflammation is rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, allograft rejection or chronic asthma.

13. The method according to claim 9, wherein said disorder resulting from coagulation and/or thrombosis is deep venous thrombosis, pulmonary embolism, thrombotic stroke, peripheral arterial thrombosis, unstable angina or myocardial infarction.

14. The method according to claim 9, wherein said disorder resulting from viral infection is Herpes Simplex.

BEST AVAILABLE COPY